Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Primary: Assessment of the pharmacokinetics (PK) of linvoseltamab, Incidence and severity of adverse events of special interest (AESI), Incidence and severity of cytokine release syndrome (CRS) with linvoseltamab, Incidence and severity of treatment-emergent adverse events (TEAEs), Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period, ORR of IV linvoseltamab as assessed by investigator, Objective response rate (ORR) as determined by an Independent Review Committee (IRC)

Secondary: Change in patient-reported global health status/QoL per EORTC QLQ-C30, DOR as determined by an investigator, measured using the International Myeloma Working Group (IMWG) criteria, Duration of response (DOR) as determined by an IRC, measured using the IMWG criteria, Effects of linvoseltamab on HRQOL and patient-reported symptoms and functioning per EuroQoL-5 Dimension-3 Level Scale [EQ-5D-3L]), Effects of linvoseltamab on HRQOL and patient-reported symptoms and functioning per Quality of Life Questionnaire-Multiple Myeloma module 20 [QLQ-MY20]), Effects of linvoseltamab on general health status per EQ-5D-3L, Effects of linvoseltamab on health-related quality of life (HRQoL) and patient-reported symptoms and functioning per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Effects of linvoseltamab on patient-reported functions and symptoms per EORTC QLQ-C30